Surgery
Gastric Sleeve vs Gastric Bypass: How a Surgeon Actually Decides
Patients arrive at the first appointment having already read a dozen comparison articles, and most of them arrive with the same question. Which one is better.
The honest answer is that the question has no general answer, and the articles that give one are usually working from numbers that were reported in a way that makes the comparison impossible. What follows is the same reasoning I use in clinic, with the sources attached so you can check any of it.
What the two operations physically do
The sleeve gastrectomy removes roughly 80 percent of the stomach along its outer curve, leaving a narrow tube. Nothing is rerouted. Food travels the same path it always did through a much smaller container, and the portion of the stomach that produces most of the body’s ghrelin is gone, which is why appetite drops rather than simply being crowded out.
The Roux-en-Y gastric bypass creates a small pouch at the top of the stomach and connects it directly to the small intestine, bypassing the rest of the stomach and the first section of the small bowel. The bypassed stomach stays in the body and keeps producing digestive fluid, which rejoins the food stream further downstream. Two things change at once: how much you can eat, and how the gut signals to the brain and pancreas.
That second mechanism is the reason bypass behaves differently in diabetes, and it is the reason the two operations are not interchangeable even though they produce similar weight loss on paper.
The weight loss numbers, and why most comparisons quote the wrong metric
Almost every comparison article you will find reports results as percent excess weight loss. That metric divides the weight you lost by the weight you were carrying above an “ideal” weight, usually a BMI of 25. The problem is that the denominator changes with your starting size. A patient starting at a BMI of 33 and a patient starting at a BMI of 55 can lose the same number of pounds and show wildly different percentages.
The Dutch Society for Metabolic and Bariatric Surgery published a position statement on exactly this in 2021, calling percent excess weight loss “inaccurate and error-sensitive when comparing weight loss within and between studies” and “inappropriate for assessing poor weight loss response and weight regain.” Percent total body weight loss is the metric that survives the comparison, because the denominator is just what you weighed on day one.
Here is what the largest American dataset shows, reported the correct way. The PCORnet Bariatric Study followed more than 46,000 adults across 41 health systems.
| Percent total body weight loss | 1 year | 5 years |
|---|---|---|
| Roux-en-Y gastric bypass | 31% | 26% |
| Sleeve gastrectomy | 25% | 19% |
| Adjustable gastric band | 14% | 12% |
Bypass produces more weight loss, and the gap is about six percentage points at one year and seven at five years. For a person starting at 300 pounds, that difference is roughly 20 pounds at the five year mark.
The randomized data points the same direction with less certainty. SLEEVEPASS, which followed 240 patients in Finland, reported five year excess weight loss of 49 percent after sleeve and 57 percent after bypass, and the trial did not meet its equivalence criteria. The Swiss SM-BOSS trial, run over the same period, found no statistically significant difference in excess weight loss at five years. Randomized trials of a few hundred patients are not powered to settle a gap this size, which is why the 46,000 patient cohort data above carries more weight on this particular question.
I am giving you both metrics on purpose. Do not put them in the same sentence when you compare clinics, because they measure different things.
Your reflux history moves this decision more than your weight does
If you already take a daily acid blocker, the reflux data below matters more to your outcome than the difference in weight loss between the two operations.
Reflux is the clearest tiebreaker
If a patient comes in already taking a proton pump inhibitor most days, the conversation gets much shorter.
The Swiss SM-BOSS trial followed patients for five years and reported that reflux went into remission in 60.4 percent of bypass patients compared with 25.0 percent of sleeve patients, and that reflux worsened in 31.8 percent of sleeve patients compared with 6.3 percent after bypass. That is not a small difference, and it holds up in the longer follow up. At ten years, SLEEVEPASS found esophagitis on endoscopy in 31 percent of sleeve patients versus 7 percent after bypass.
A 2024 meta-analysis of the five year randomized data found higher odds of revisional surgery for reflux after sleeve, with an odds ratio of 11.47. The confidence interval on that estimate runs from 1.83 to 71.69, which is very wide, so the direction is solid and the magnitude is not. The same analysis found roughly four times the odds of being on a proton pump inhibitor, with a tighter interval of 2.31 to 6.55. In SM-BOSS, nine sleeve patients, or 8.4 percent, were converted to a bypass because of reflux. No bypass patients in either trial were converted for that reason.
The Barrett’s esophagus question deserves a more careful answer than it usually gets. Alarming figures circulate. The ten year randomized data from SLEEVEPASS, where 77 percent of surviving patients actually underwent gastroscopy rather than self-reporting, found new Barrett’s in 4 percent after sleeve and 4 percent after bypass, with no significant difference. Non-randomized cohort studies report considerably higher rates, some approaching one in five, and the reported figure tracks closely with how aggressively each study looked for it and how long it followed patients.
What I tell patients is that reflux after sleeve is common and manageable, Barrett’s is uncommon, and if you already have significant reflux the bypass is the operation that treats it rather than the one that risks making it worse.
Diabetes
Both operations put type 2 diabetes into remission at rates no medication has matched, and bypass has a modest edge.
The PCORnet analysis of 9,710 patients with diabetes found five year remission in 86.1 percent after bypass and 83.5 percent after sleeve. The more meaningful difference is what happened after remission: 41.6 percent of sleeve patients relapsed compared with 33.1 percent after bypass.
The randomized data is less dramatic because the numbers are smaller. SLEEVEPASS reported remission in 37 percent of sleeve patients and 45 percent after bypass at five years, a difference that did not reach statistical significance in a trial of that size.
For a patient with long standing insulin dependent diabetes, that gap is usually enough to point toward bypass. For a patient with recent, diet controlled diabetes, either operation is reasonable and the decision gets made on other grounds.
The five year picture is where the two operations separate
The two look similar in the first year. By year five bypass shows more additional procedures, and sleeve shows more reflux along with more revisions done because of it.
What happens in the five years after
This is the part most comparison articles skip, and it is the part patients ask about at year three.
The PCORnet group published the follow up data in JAMA Surgery in 2020. Across 33,560 patients, the adjusted five year cumulative incidence of any additional operation or intervention was 12.3 percent after bypass and 8.9 percent after sleeve. Endoscopy accounted for a larger share of the gap than reoperation did. Hospitalization for any cause ran 38.3 percent after bypass and 32.8 percent after sleeve. There was no difference in all cause mortality between the two.
Note the wording on that outcome, because it is frequently misquoted. The endpoint was any operation or intervention, which includes endoscopic procedures, not just a second abdominal operation.
Read that alongside the reflux data and you get the real trade. Bypass produces more weight loss, better reflux control, and slightly better diabetes durability. Sleeve is the simpler operation with fewer downstream procedures. Neither of those is a defect. They are different shapes of the same decision.
Vitamins for the rest of your life
Both operations require lifelong supplementation, and the requirement is not optional after either one.
The ASMBS nutritional guidelines call for at least 12 mg of thiamine daily, 350 to 500 mcg of oral vitamin B12 daily or 1,000 mcg by injection monthly, vitamin D titrated to keep the 25-hydroxy level above 30 ng/mL, 1,200 to 1,500 mg of calcium citrate in divided doses, and elemental iron at 45 to 60 mg daily for menstruating women and for anyone at elevated risk after either procedure. Two daily multivitamins, indefinitely.
Bypass carries the higher deficiency burden because it bypasses the duodenum, where much of your iron and calcium absorption happens. That does not make sleeve a free pass. Deficiency after sleeve is common enough that the supplementation protocol is the same.
If a program is not talking to you about this at the first visit, that tells you something about the program.
Who actually qualifies
Most of what you will read online is out of date on this point. The 1991 NIH consensus set the threshold at a BMI of 40, or 35 with a related condition, and those numbers are still quoted on comparison pages written last year.
ASMBS and IFSO replaced them in 2022. Surgery is now recommended at a BMI of 35 or above regardless of whether you have any related condition, and it should be considered at a BMI of 30 to 34.9 in the presence of metabolic disease. For patients of Asian descent, obesity is defined starting at a BMI of 25 to 27.5, and surgery is considered from 27.5.
If you were told a few years ago that you were not heavy enough to qualify, the guideline has changed since then.
The regain question, and the number you may have read
Cleveland Clinic’s patient article states that up to 76 percent of patients experience weight recurrence. That figure gets repeated widely, and it deserves context.
It traces to a 2016 systematic review of sleeve gastrectomy only, which reported that regain rates ranged from 5.7 percent at two years to 75.6 percent at six years. The authors of that review explicitly noted that the studies they pooled used a range of different definitions of weight regain and called for the field to standardize them. So 76 percent is the top of a wide range, from sleeve patients alone, measured with no agreed definition.
Some regain is normal and expected after both operations. Most people reach their lowest weight somewhere between 12 and 18 months and drift up a modest amount after that. The clinically meaningful question is not whether the number on the scale moves at all, but whether the metabolic improvements hold. There is no single validated regain percentage for bypass to set against that 76 percent, and anyone quoting one should be asked where it came from.
Both operations are done same day at Legacy Surgery Center
Most patients leave the first visit knowing which two or three factors are driving their own decision.
How the decision actually gets made
In clinic, the conversation runs through a short list.
Do you have reflux now, and how much. That is the strongest single pointer, and it points to bypass.
How long have you had diabetes, and are you on insulin. Longer and insulin dependent points to bypass.
What medications do you take, and do any of them have narrow absorption windows. Bypass changes how some drugs are absorbed, and that occasionally decides it.
What is your starting BMI, and how much do you need to lose. At the higher end, the extra weight loss from bypass matters more.
How do you feel about a rearranged anatomy. Some patients want the simpler operation and are willing to accept the smaller result, and that is a legitimate preference rather than a wrong answer.
Do you have a history of anemia, or are you a menstruating woman with borderline iron. That tilts toward sleeve.
Nobody should leave the first appointment with a decision made. You should leave it understanding which two or three factors are actually driving yours. If you would rather work through them with me than with a comparison article, book a consultation.
Both are done same day here
At Karas Weight Loss and Wellness, sleeve and bypass are both performed at an ambulatory surgery center, and most patients go home the same day rather than staying overnight in a hospital. The operation itself takes about the same amount of time either way. What changes is the building, the bill, and how long you sit in a bed after you wake up.
Common questions
Can a sleeve be converted to a bypass later? Yes, and it is a recognized operation rather than a rescue. The two most common reasons are reflux that does not respond to medication and inadequate weight loss. In SM-BOSS, 8.4 percent of sleeve patients were converted for reflux within five years.
Which one is safer? Both are safe operations by any modern standard. The GENEVA study collected data on 7,704 patients across 185 centers in 42 countries. In its propensity matched analysis of 2,085 matched pairs, 30 day complications occurred in 6.1 percent of sleeve patients and 7.9 percent of bypass patients, a difference that did not reach statistical significance. Mortality across the whole cohort was about 0.1 percent.
Will I lose more weight with bypass? On average, yes, by roughly six to seven percentage points of total body weight. Individual results vary far more than the difference between the two operations, which is why the average is a poor way to choose.
Is one better for someone who has already tried a GLP-1? Neither operation is disqualified by prior medication use, and many patients arrive having lost some weight on semaglutide or tirzepatide and then plateaued. That history is useful information rather than a strike against you.
How soon can I go back to work? Most patients doing desk work return within one to two weeks after either operation. Physical work takes longer.
Talk to Dr. Karas
Which operation is right for you comes down to your reflux history, how long you have had diabetes, what medications you take, and where you are starting from. That is a conversation, not something to settle from a table of averages.
Sources
Arterburn D, et al. Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss. Ann Intern Med. 2018;169(11):741-750.
Courcoulas A, et al. Interventions and Operations 5 Years After Bariatric Surgery. JAMA Surg. 2020;155(3):194-204.
McTigue KM, et al. Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass. JAMA Surg. 2020;155(5):e200087.
Salminen P, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years (SLEEVEPASS). JAMA. 2018;319(3):241-254.
Salminen P, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years. JAMA Surg. 2022;157(8):656-666.
Peterli R, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity (SM-BOSS). JAMA. 2018;319(3):255-265.
Memon MA, Osland E, Yunus RM, Hoque Z, Alam K, Khan S. Gastroesophageal reflux disease outcomes after laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass: meta-analysis of randomized controlled trials. Surg Endosc. 2024.
Lauti M, et al. Weight Regain Following Sleeve Gastrectomy: a Systematic Review. Obes Surg. 2016;26(6):1326-1334.
Eisenberg D, et al. 2022 ASMBS and IFSO Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2022;18(12):1345-1356.
Parrott J, et al. ASMBS Integrated Health Nutritional Guidelines, 2016 Update: Micronutrients. Surg Obes Relat Dis. 2017;13(5):727-741.
van de Laar AW, et al. Reporting Weight Loss 2021: Position Statement of the Dutch Society for Metabolic and Bariatric Surgery. Obes Surg. 2021;31(10):4607-4611.
Singhal R, et al. 30-day morbidity and mortality of sleeve gastrectomy, Roux-en-Y gastric bypass and one anastomosis gastric bypass: a propensity score matched analysis of the GENEVA data. Int J Obes. 2022;46:750-757.